Search results
Results from the WOW.Com Content Network
There is a high risk of withdrawal syndrome which may occur if the dose is decreased or the medication is completely stopped. [5] [8] It is unclear if use during pregnancy or breastfeeding is safe. [9] Desvenlafaxine was approved for medical use in the United States in 2008. [5] In Europe its application for use was denied in 2009. [6] In 2022 ...
Another pharmaceutical company is recalling a blood pressure medication that could increase the risk of cancer if taken in large amounts. On Wednesday, Lupin Pharmaceuticals recalled four lots of ...
Antihypertensive therapy seeks to prevent the complications of high blood pressure, such as stroke, heart failure, kidney failure and myocardial infarction. Evidence suggests that a reduction of blood pressure by 5 mmHg can decrease the risk of stroke by 34% and of ischaemic heart disease by 21%.
Pfizer recalled certain lots of its high blood pressure medication for containing high levels of nitrosamines, which can lead to increased cancer risk.
For most people, recommendations are to reduce blood pressure to less than or equal to somewhere between 140/90 mmHg and 160/100 mmHg. [2] In general, for people with elevated blood pressure, attempting to achieve lower levels of blood pressure than the recommended 140/90 mmHg will create more harm than benefits, [3] in particular for older people. [4]
As a whole, anxiety meds are some of the most widely used medications in the United States — in 2019, nearly 16 percent of American adults were prescribed some type of psychiatric medication.
Guanfacine, sold under the brand name Tenex (immediate-release) and Intuniv (extended-release) among others, is an oral alpha-2a agonist medication used to treat attention deficit hyperactivity disorder (ADHD) and high blood pressure. [3] [10] Common side effects include sleepiness, constipation, and dry mouth. [10]
Contraindications include the coadministration of terfenadine, astemizole, cisapride, pimozide, or carbamazepine.Nefazodone is contraindicated in patients who were withdrawn from nefazodone because of evident liver injury as well as those that have shown hypersensitivity to the drug, its inactive ingredients, or other phenylpiperazine antidepressants.